Overview CRITIC - Treatment of Candidemia and Invasive Candidiasis Status: Completed Trial end date: 2009-01-01 Target enrollment: Participant gender: Summary Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture Phase: Phase 4 Details Lead Sponsor: Gilead SciencesTreatments: Amphotericin BLiposomal amphotericin B